Thyrocare Tech.

Which are the latest news on Thyrocare Tech.?

Why is Thyrocare Technologies Ltd falling/rising?

As of 05-Sep, Thyrocare Technologies Ltd's stock price is at 576.15, down 0.23%. The stock faces short-term challenges with a decline in price and investor participation, despite strong long-term performance and positive financial indicators.

As of 05-Sep, Thyrocare Technologies Ltd's stock price is currently at 576.15, reflecting a decrease of 1.35 points or 0.23%. The stock has shown a negative performance in the short term, with a decline of 1.51% over the past week and 4.67% over the past month. This downward trend is compounded by a significant drop in investor participation, as evidenced by a 45.95% decrease in delivery volume compared to the 5-day average.<BR><BR>Despite these short-term challenges, the company has demonstrated strong long-term performance, with a year-to-date increase of 29.18% and a remarkable 221.48% rise over the past three years. The company has consistently reported positive results, including a net profit growth of 33.07% and has maintained a net-debt-free status. However, the stock's valuation appears high, with a price-to-book value of 15.7, which is considered expensive compared to its peers. Additionally, the fact that 100% of promoter shares are pledged may contribute to downward pressure on the stock price, particularly in a falling market.<BR><BR>In summary, while Thyrocare Technologies Ltd has a strong historical performance and positive financial indicators, the current decline in stock price can be attributed to short-term market pressures, reduced investor participation, and concerns over high valuations and pledged shares.

Who are in the management team of Thyrocare Tech.?

The management team of Thyrocare Tech includes Rahul Guha (Managing Director & CEO), Ramjee Dorai (Company Secretary), and several independent and non-executive directors, totaling 11 key members who provide diverse expertise for the company's operations and strategy.

The management team of Thyrocare Tech includes the following individuals:<BR><BR>1. **Rahul Guha** - Managing Director & CEO<BR>2. **Ramjee Dorai** - Company Secretary & Compliance Officer<BR>3. **Gopal Shivram Hegde** - Independent Director<BR>4. **Neetin Shivajirao Desai** - Independent Director<BR>5. **Vishwas Madhav Kulkarni** - Independent Director<BR>6. **Indumati Gopinathan** - Independent Director<BR>7. **Dhaval Shah** - Non-Executive & Non-Independent Director<BR>8. **Dharmil Sheth** - Non-Executive & Non-Independent Director<BR>9. **Hardik Dedhia** - Non-Executive & Non-Independent Director<BR>10. **Prapti Ishwar Gilada** - Independent Director<BR>11. **Harshil Jiten Vora** - Independent Director<BR><BR>This diverse team brings a range of expertise to the company, supporting its operations and strategic direction.

What does Thyrocare Tech. do?

Thyrocare Technologies Ltd is a healthcare services company specializing in affordable diagnostic services. As of June 2026, it reported net sales of 240 Cr and a net profit of 52 Cr, with a market cap of INR 9,226 Cr.

Overview:<BR>Thyrocare Technologies Ltd operates in the healthcare services industry, providing quality diagnostic services at affordable costs.<BR><BR>History:<BR>The company was incorporated in January 2000 and continues to operate in the healthcare sector. As of the latest quarterly results for June 2026, it reported net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 240 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 52 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 9,226 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 53.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 1.59% <BR>Debt Equity: -0.29 <BR>Return on Equity: 28.68% <BR>Price to Book: 15.96 <BR><BR>Contact Details:<BR>Address: D-37/1 TTC Industrial Area, MIDC Turbhe Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27622762 <BR>Email: investor_relations@thyrocare.com <BR>Website: http://www.thyrocare.com

Who are the peers of the Thyrocare Tech.?

Thyrocare Tech.'s peers include Vijaya Diagnostics, Indegene, Metropolis Healthcare, Suven Life Sciences, Vimta Labs, Krsnaa Diagnostics, Suraksha Diagnostics, and Tarsons Products. In terms of management risk, growth, capital structure, and returns, Thyrocare Tech. performs well but is outpaced by Suven Life Sciences in returns.

Peers: The peers of Thyrocare Tech. are Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., and Tarsons Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vijaya Diagnost., Thyrocare Tech., and Suraksha Diagno., while Average management risk is found at Indegene, Metropolis Healt, Vimta Labs, and Krsnaa Diagnost., and the rest. Below Average management risk is noted at Suven Life Scie. and Tarsons Products. Growth is classified as Good for Suraksha Diagno., while Below Average growth is seen at Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., and Tarsons Products. Excellent capital structure is present at Vijaya Diagnost., Thyrocare Tech., Vimta Labs, and Indegene, while Good capital structure is noted at Krsnaa Diagnost. and Suraksha Diagno., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Suven Life Scie. has the highest 1-year return at 84.49%, while Krsnaa Diagnost. has the lowest at -29.39%. Thyrocare Tech.'s 1-year return of 42.56% is significantly higher than Krsnaa Diagnost.'s but lower than Suven Life Scie.'s. Additionally, Krsnaa Diagnost. is the only peer with a negative six-month return.

How big is Thyrocare Tech.?

As of 31st August, Thyrocare Technologies Ltd has a market capitalization of 9,226.00 Cr, with recent net sales of 876.03 Cr and net profit of 176.31 Cr over the last four quarters.

As of 31st August, <BR><BR>Market Cap: Thyrocare Technologies Ltd has a market capitalization of 9,226.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 876.03 Cr, while the sum of Net Profit for the same period is 176.31 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 585.50 Cr and Total Assets valued at 731.56 Cr.

Are Thyrocare Technologies Ltd latest results good or bad?

Thyrocare Technologies Ltd's latest results are positive, with a 34.06% increase in net profit and a 24.34% rise in revenue for Q1 FY27, indicating strong demand and effective cost management. The company boasts impressive operating margins and a high return on equity, although its current valuation is considered "very expensive."

Thyrocare Technologies Ltd's latest results can be considered quite good. In Q1 FY27, the company reported a net profit of ₹52.19 crores, reflecting a significant year-on-year increase of 34.06%. Additionally, revenue grew by 24.34% compared to the same quarter last year, reaching ₹240.02 crores. This growth indicates strong demand for their diagnostic services and successful expansion of their testing portfolio.<BR><BR>The operating margin stood at 32.19%, which is impressive and demonstrates effective cost management. Furthermore, the return on equity (ROE) is notably high at 28.68%, showcasing the company's ability to generate substantial returns from its equity.<BR><BR>Overall, Thyrocare has shown robust financial performance, with strong revenue and profit growth, industry-leading margins, and a solid balance sheet with no long-term debt. These factors contribute to a positive outlook for the company, despite its current valuation being considered "very expensive."

Should I buy, sell or hold Thyrocare Technologies Ltd?

When is the next results date for Thyrocare Technologies Ltd?

The next results date for Thyrocare Technologies Ltd is 07 May 2026.

The next results date for Thyrocare Technologies Ltd is scheduled for 07 May 2026.

Is Thyrocare Tech. technically bullish or bearish?

As of December 2, 2025, Thyrocare Tech. shows a mildly bullish trend supported by bullish MACD and moving averages, but tempered by a mildly bearish KST and Dow Theory signals, indicating caution in the current market.

As of 2 December 2025, the technical trend for Thyrocare Tech. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and daily moving averages indicating bullish momentum. However, the KST shows a mildly bearish signal on the weekly chart, which tempers the overall bullish outlook. Bollinger Bands are also indicating mildly bullish conditions on both weekly and monthly charts. The RSI shows no significant signals, and Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, while there are bullish indicators present, the mildly bearish signals suggest caution in the current market environment.

What is the bonus history of Thyrocare Tech.?

Thyrocare Technologies Ltd recently announced a 2:1 bonus issue, with an ex-date of November 28, 2025. Shareholders will receive two additional shares for every one share held as of that date.

Thyrocare Technologies Ltd has a recent bonus issue where they announced a 2:1 bonus. The ex-date for this bonus is set for November 28, 2025. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also November 28, 2025. If you have any further questions about Thyrocare or its corporate actions, feel free to ask!

How has been the historical performance of Thyrocare Tech.?

Thyrocare Tech. has shown steady growth in net sales and profits, with net sales increasing from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25, and profit after tax rising to 92.19 Cr in Mar'25. The company has demonstrated resilience with improved earnings per share and strong cash flow from operating activities.

Answer:<BR>The historical performance of Thyrocare Tech. shows a steady growth in net sales and profits over the years, with a notable increase in recent years.<BR><BR>Breakdown:<BR>Thyrocare Tech. has demonstrated a consistent upward trend in net sales, rising from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 687.35 Cr in Mar'25, up from 571.88 Cr in Mar'24. The company's total expenditure also increased, amounting to 496.99 Cr in Mar'25 compared to 434.45 Cr in Mar'24. Operating profit, however, saw fluctuations, peaking at 264.14 Cr in Mar'22 before declining to 205.19 Cr in Mar'25. Profit before tax increased to 146.88 Cr in Mar'25 from 95.59 Cr in Mar'24, while profit after tax rose to 92.19 Cr in Mar'25, up from 69.10 Cr in Mar'24. The earnings per share (EPS) improved to 17.27 in Mar'25 from 13.36 in Mar'24. On the balance sheet, total assets grew to 684.22 Cr in Mar'25 from 629.06 Cr in Mar'24, while total liabilities also increased to 684.22 Cr in Mar'25. Cash flow from operating activities showed a positive trend, reaching 191 Cr in Mar'25, indicating strong operational performance. Overall, Thyrocare Tech. has shown resilience and growth in its financial metrics over the years.

Has Thyrocare Tech. declared dividend?

Yes, Thyrocare Technologies Ltd has declared a 70% dividend, amounting to ₹21 per share, with an ex-date of July 25, 2025. The company has demonstrated strong total returns across various periods, reflecting its commitment to shareholder value.

Thyrocare Technologies Ltd has declared a 70% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 70%<BR>- Amount per share: 21<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 1.69%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 6.28%, the dividend return was 2.37%, resulting in a total return of 8.65%.<BR><BR>Over the past 6 months, the price return reached 79.35%, with a dividend return of 3.81%, culminating in a total return of 83.16%.<BR><BR>For the 1-year period, the price return was 43.61%, the dividend return was 3.11%, leading to a total return of 46.72%.<BR><BR>In the 2-year span, the price return stood at 123.52%, with a dividend return of 8.53%, resulting in a total return of 132.05%.<BR><BR>Over the last 3 years, the price return was 89.03%, the dividend return was 9.93%, giving a total return of 98.96%.<BR><BR>In the 4-year period, the price return was 11.77%, with a dividend return of 6.78%, resulting in a total return of 18.55%.<BR><BR>Finally, in the 5-year period, the price return was 25.73%, the dividend return was 9.86%, leading to a total return of 35.59%.<BR><BR>Overall, Thyrocare Technologies Ltd has shown a strong performance with significant total returns across various periods, supported by a declared dividend, indicating a commitment to returning value to shareholders.

Who are the top shareholders of the Thyrocare Tech.?

The top shareholder of Thyrocare Technologies is Docon Technologies Private Limited, holding 71.06%. Other significant shareholders include Nippon Life India Trustee Ltd at 7.05%, mutual funds with 12.97%, foreign institutional investors at 2.41%, and individual investors with 9.21%.

The top shareholders of Thyrocare Technologies include a mix of promoters, mutual funds, and individual investors. The majority shareholder is Docon Technologies Private Limited, which holds a significant 71.06% of the company. Promoters collectively have pledged their holdings entirely. Among public shareholders, Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund, is the largest with a holding of 7.05%. Additionally, mutual funds account for 12.97% of the shares, held by seven different schemes, while foreign institutional investors (FIIs) hold 2.41%. Individual investors collectively own 9.21% of the company.

Is Thyrocare Tech. overvalued or undervalued?

As of July 3, 2025, Thyrocare Technologies is considered very expensive and overvalued due to its high PE ratio of 59.09, Price to Book Value of 9.91, and EV to EBITDA of 27.57, despite a strong ROCE of 35.59% and a one-year stock return of 59.53%.

As of 3 July 2025, the valuation grade for Thyrocare Technologies has moved from expensive to very expensive, indicating a significant concern regarding its current pricing. The company is deemed overvalued based on its high PE ratio of 59.09, a Price to Book Value of 9.91, and an EV to EBITDA of 27.57. These ratios suggest that investors are paying a premium for the stock relative to its earnings and book value.<BR><BR>In comparison to its peers, Thyrocare's valuation appears excessive, especially when looking at Max Healthcare, which has a PE of 112.13, and Apollo Hospitals with a PE of 75.12. While Thyrocare's ROCE stands at a robust 35.59%, the high PEG ratio of 2.01 further emphasizes the overvaluation concern. Additionally, despite a strong one-year stock return of 59.53% compared to the Sensex's 4.07%, the elevated valuation metrics suggest that the stock may not sustain this growth, reinforcing the conclusion that Thyrocare Technologies is overvalued.